Review top news and interview highlights from the week ending September 9, 2022.
Welcome to CGTLive’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.
Patients receiving CAR T-cell therapy or bispecific antibody therapies as first salvage therapy had an ORR of 84%.
The chief medical officer of Passage Bio discussed research needs in FTD.
SLN124 was well-tolerated in a previous clinical trial involving healthy volunteers.
iECURE is planning to submit an IND for GTP-506 in mid-2023.